Allogeneic marrow transplantation from HLA genotypically identical siblings have become life-saving therapy for patients with various congenital and acquired diseases of the immune and hematopoietic systems. Graft-versus-host disease (GVHD), however, remains a significant cause of morbidity and mortality. Nonspecific immune suppression developed through empirical trials has provided increasingly better GVHD control, but these agents are potentially toxic, they delay immune reconstitution and increase the risk of infection. Less than 30% of patients have an HLA identical sibling and many are denied the opportunity for a potentially curative treatment for otherwise fatal disease. The development of a national registry of potential marrow donors has made it possible to access a centralized file of more than 1.5 million HLA typed volunteers. GVHD is increased in both incidence and severity in unrelated donor transplants. This may be explained by an inability to achieve sufficient donor and recipient HLA matching, however incompatibility for non-HLA minor histocompatibility antigens (mHA) may also play a role. Improved HLA typing alone will not solve all problems related to donor selection because the extreme nature of HLA polymorphism in human populations dictates that many patients will never find a perfectly matched donor. Successful management of these patients will depend on improving our understanding of T cell responses to alloantigen and development of more rational effective approaches to achieving tolerance. There are four scientific projects in this Program Project grant, and one administrative and shared resources core. The first Project is aimed at discovering new polymorphic genes residing within the HLA class I region, ad characterizing the function and expression of these nonclassical class I genes. The second Project is aimed at defining the antigen presenting function of human CD34+ stem cells and peripheral blood progenitor cells, and identifying costimulatory molecules required for T cell responses to alloantigens expressed by hematopoietic cells. The third Project involves studies of donor T cell responses to host the classical diversity of this response and the identification of T cells responsible for GVHD. The fourth Project is directed to studies of peptide ligands presented by class I HLA-A, B and C molecules, the peptide motifs that define alloantigens and the role that peptides selection may play in determining the repertoire of the T cell response in marrow allografts.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Program Projects (P01)
Project #
5P01AI033484-08
Application #
2886807
Study Section
Allergy & Clinical Immunology-1 (AITC)
Program Officer
Prasad, Shiv A
Project Start
1992-09-30
Project End
2000-08-31
Budget Start
1999-09-01
Budget End
2000-08-31
Support Year
8
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Fred Hutchinson Cancer Research Center
Department
Type
DUNS #
075524595
City
Seattle
State
WA
Country
United States
Zip Code
98109
McCune, Jeannine S; Storer, Barry; Thomas, Sushma et al. (2018) Inosine Monophosphate Dehydrogenase Pharmacogenetics in Hematopoietic Cell Transplantation Patients. Biol Blood Marrow Transplant 24:1802-1807
Wolff, D; Greinix, H; Lee, S J et al. (2018) Biomarkers in chronic graft-versus-host disease: quo vadis? Bone Marrow Transplant 53:832-837
McDonald, George B; Tabellini, Laura; Storer, Barry E et al. (2017) Predictive Value of Clinical Findings and Plasma Biomarkers after Fourteen Days of Prednisone Treatment for Acute Graft-versus-host Disease. Biol Blood Marrow Transplant 23:1257-1263
Inamoto, Yoshihiro; Martin, Paul J; Paczesny, Sophie et al. (2017) Association of Plasma CD163 Concentration with De Novo-Onset Chronic Graft-versus-Host Disease. Biol Blood Marrow Transplant 23:1250-1256
McDonald, George B; Tabellini, Laura; Storer, Barry E et al. (2015) Plasma biomarkers of acute GVHD and nonrelapse mortality: predictive value of measurements before GVHD onset and treatment. Blood 126:113-20
Nakasone, Hideki; Tian, Lu; Sahaf, Bita et al. (2015) Allogeneic HY antibodies detected 3 months after female-to-male HCT predict chronic GVHD and nonrelapse mortality in humans. Blood 125:3193-201
Warren, E H; Deeg, H J (2013) Dissecting graft-versus-leukemia from graft-versus-host-disease using novel strategies. Tissue Antigens 81:183-93
Inamoto, Yoshihiro; Storer, Barry E; Petersdorf, Effie W et al. (2013) Incidence, risk factors, and outcomes of sclerosis in patients with chronic graft-versus-host disease. Blood 121:5098-103
Warren, Edus H; Matsen 4th, Frederick A; Chou, Jeffrey (2013) High-throughput sequencing of B- and T-lymphocyte antigen receptors in hematology. Blood 122:19-22
Hansen, John A; Hanash, Samir M; Tabellini, Laura et al. (2013) A novel soluble form of Tim-3 associated with severe graft-versus-host disease. Biol Blood Marrow Transplant 19:1323-30

Showing the most recent 10 out of 134 publications